Donald Trump's order on psychedelic drugs sent shares of companies in the space surging. RFK Jr and Joe Rogan were present at the signing.

A new executive order could usher in psychedelics as the “key next wave” of mental health therapies, according to analysts at RBC Capital Markets.

The Food and Drug Administration fulfilled a key part of President Trump's recent federal green light on psychedelics research on Friday by granting expedited review for three companies studying three drugs to treat mental conditions.

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a surge in investment in companies researching and developing psychedelic drugs to treat mental health issues.

While the FDA did not announce the recipient names of the Commissioner’s National Priority Vouchers, the agency’s descriptions of the awarded products match those in development at Compass Pathways, Transcend Therapeutics and Usona Institute.

AbbVie’s (NYSE:ABBV) move to buy New York-based psychedelic drug developer Gilgamesh Pharmaceuticals in a deal worth around $1B, according to Bloomberg News, rallied the psychedelic space on Thursday. Citing people familiar with the matter, Bloomberg ...

Psychedelic Science, billed as the country’s largest conference focused on mind-altering substances, is preparing to return to Denver this month, bringing with it scientists, policymakers, and activists to discuss the latest advancements in their ...

A new executive order could make it easier for researchers studying how psychedelic drugs such as psilocybin, LSD and ibogaine may be useful in medicine